LENZ
LENZ Therapeutics Surpasses 50% Growth Milestone in Q3 2026, Sets Sights on Consumer-Led Commercial Model
LENZ Therapeutics has marked a significant milestone in its third quarter 2026 financial results, reporting more than 50% growth in both product revenue and total prescriptions. The company's President and Chief Executive Officer, Afschin Skjalm Paddock, highlighted the importance of this step forward for LENZ and its VIZZ